Foundation Fighting Blindness: Sepul Bio Launches Phase 2b Clinical Trial for USH2A RNA Therapy
December 14, 2024
December 14, 2024
COLUMBIA, Maryland, Dec. 14 -- The Foundation Fighting Blindness issued the following news:
* * *
Known as ultevursen, the USH2A RNA therapy was licensed from ProQR.
* * *
Sepul Bio, a business unit of Laboratories Thea developing RNA therapies for inherited retinal diseases, has dosed the first patient in a Phase 2b clinical trial for ultevursen, an emerging RNA therapy for people with retinitis pigmentosa or Usher syndrome caused by mutations . . .
* * *
Known as ultevursen, the USH2A RNA therapy was licensed from ProQR.
* * *
Sepul Bio, a business unit of Laboratories Thea developing RNA therapies for inherited retinal diseases, has dosed the first patient in a Phase 2b clinical trial for ultevursen, an emerging RNA therapy for people with retinitis pigmentosa or Usher syndrome caused by mutations . . .